Facilitating Longitudinal Exposure-Response Modeling of a Composite Endpoint Using the Joint Modeling of Sparsely and Frequently Collected Subcomponents-Reference-Cited by-同舟云学术

Facilitating Longitudinal Exposure-Response Modeling of a Composite Endpoint Using the Joint Modeling of Sparsely and Frequently Collected Subcomponents

Published:2020-05-26 Issue:4 Volume:22 Page:
ISSN:1550-7416
Container-title:The AAPS Journal
language:en
Short-container-title:AAPS J

Author:

Hu Chuanpu,Zhou Honghui,Sharma Amarnath

Publisher

Springer Science and Business Media LLC

Subject

Pharmaceutical Science

Link

https://link.springer.com/content/pdf/10.1208/s12248-020-00452-1.pdf

Reference38 articles.

1. Overgaard RV, Ingwersen SH, Tornoe CW. Establishing good practices for exposure-response analysis of clinical endpoints in drug development. CPT Pharmacometrics Syst Pharmacol. 2015;4(10):565–75.

2. Hu C, Zhou H, Sharma A. Landmark and longitudinal exposure-response analyses in drug development. J Pharmacokinet Pharmacodyn. 2017;44(5):503–7.

3. Karlsson MO, Holford NHG. A tutorial on visual predictive checks [updated 2008]. Available from: https://www.page-meeting.org/?abstract=1434.

4. Hu C, Adedokun OJ, Chen Y, Szapary PO, Gasink C, Sharma A, et al. Challenges in longitudinal exposure-response modeling of data from complex study designs: a case study of modeling CDAI score for ustekinumab in patients with Crohn's disease. J Pharmacokinet Pharmacodyn. 2017;44(5):425–36.

5. Hu C, Adedokun OJ, Zhang L, Sharma A, Zhou H. Modeling near-continuous clinical endpoint as categorical: application to longitudinal exposure-response modeling of Mayo scores for golimumab in patients with ulcerative colitis. J Pharmacokinet Pharmacodyn. 2018;45(6):803–16.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Indirect modeling of derived outcomes: Are minor prediction discrepancies a cause for concern?;CPT: Pharmacometrics & Systems Pharmacology;2024-08-14

2. Model‐Informed Assessment of Probability of Phase 3 Success for Ritlecitinib in Patients with Moderate‐to‐Severe Ulcerative Colitis;Clinical Pharmacology & Therapeutics;2024-04-16